AVEO Pharmaceuticals, Inc. (AVEO) Coverage Initiated by Analysts at B. Riley
Equities researchers at B. Riley started coverage on shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) in a research note issued on Monday. The brokerage set a “buy” rating and a $5.00 price target on the biopharmaceutical company’s stock. B. Riley’s price objective suggests a potential upside of 65.56% from the company’s current price.
Several other brokerages have also recently issued reports on AVEO. Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. Piper Jaffray Companies increased their target price on shares of AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a report on Monday, August 28th. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. Finally, Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $3.81.
AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $3.02 on Monday. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $4.24.
A number of institutional investors have recently modified their holdings of AVEO. RA Capital Management LLC bought a new position in AVEO Pharmaceuticals during the 2nd quarter worth about $18,727,000. Vanguard Group Inc. lifted its position in shares of AVEO Pharmaceuticals by 48.6% during the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares during the last quarter. EAM Investors LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at about $1,979,000. Paloma Partners Management Co purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at about $184,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of AVEO Pharmaceuticals during the third quarter valued at about $550,000. Institutional investors own 53.94% of the company’s stock.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.